IL1B and cryopyrin-associated periodic syndrome: In 2009, the FDA approved canakinumab, a human monoclonal antibody that specifically and selectively targets IL-1β, for treating periodic fever syndromes, including familial Mediterranean fever (FMF), CAPS, and Still’s disease (Sanz-Cabanillas et al., 2023).